News
Ironwood Pharmaceuticals Will Present Late-breaking Data During The 2024 Digestive Disease Week Meeting From Its Phase 3 STARS Trial Of Apraglutide For Short Bowel Syndrome With Intestinal Failure
21 May 24
Biotech, News, Health Care, General
Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $14
10 May 24
News, Price Target, Analyst Ratings
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
9 May 24
News, Intraday Update, Markets, Movers
12 Health Care Stocks Moving In Thursday's Pre-Market Session
9 May 24
Movers
Ironwood Pharmaceuticals Lowers 2024 Guidance: Now Expects Sales Between $405M-$425M (Prior $435M-$455M) Vs. 447.9M Consensus; Sees Adjusted EBITDA Above $120M
9 May 24
Earnings, News, Guidance
Ironwood Pharmaceuticals Q1 2024 Adj EPS $(0.02) Misses $0.19 Estimate, Sales $74.877M Miss $105.804M Estimate
9 May 24
Earnings, Earnings Misses, News
Ironwood Pharmaceuticals Announces Results From Phase 2 Exploratory STARGAZE Trial of Apraglutide For Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease
28 Mar 24
Biotech, News, Health Care, General
Press releases
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
30 May 24
Press Releases
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
21 May 24
Press Releases
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
9 May 24
Press Releases
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
6 May 24
Press Releases
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
1 May 24
Press Releases
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
25 Apr 24
Press Releases
Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
28 Mar 24
Press Releases